Phase II trial of NF-kappa-B decoy oligonucleotide for the treatment of skin diseases.
Phase of Trial: Phase II
Latest Information Update: 25 Dec 2009
At a glance
- Drugs NF kappa B Decoy-AnGes MG (Primary)
- Indications Dermatitis; Psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Meyer Pharmaceuticals; Transcription Factor Therapeutics
- 05 Sep 2009 New trial record.